Healthcare Access
6 articles on Healthcare Access, written by Shotlee and medically reviewed for clinical accuracy.
Peptide Panic: Why 'Plateau Panic' Hits Hard When Suppliers Disappear
The abrupt closure of a major peptide supplier has sent shockwaves through the patient community, revealing the inherent risks of gray-market access and highlighting the critical need for regulated, physician-guided peptide therapy.
8 min read
Generic GLP-1s: Hope for Affordable Weight Loss & Diabetes Care?
As brand-name GLP-1 medications such as Ozempic and Wegovy become increasingly sought after for weight loss and diabetes management, many Canadians face significant cost barriers. The anticipation surrounding the approval of generic semaglutide offers a beacon of hope for improved accessibility and affordability. This article delves into the current landscape, patient stories, and expert insights on the journey towards more accessible peptide therapies.
7 min read
Amazon One Medical Launches GLP-1 Weight Management Program
Amazon One Medical has launched a new weight management program featuring GLP-1 medications, providing transparent pricing and dedicated primary care oversight. With GLP-1 pills starting at $25 per month with insurance or $149 cash-pay, and injectables at $299, this initiative addresses key barriers like cost. Available nationwide with rapid delivery, it builds on Amazon's growing healthcare ecosystem.
5 min read
GLP-1 Envy Was Just the Beginning: Hims & Hers Super Bowl Ad
A Hims & Hers Super Bowl ad provocatively claims 'Rich people live longer,' selling telehealth access to GLP-1s, peptides, and testosterone like the elite. But as compounded drugs face DOJ scrutiny, is this democratizing care or risking safety? Dive into the ad, cultural envy, and expert concerns.
5 min read
Coverage Unlocks Semaglutide's Potential for Obesity & Diabetes
Semaglutide, a powerful GLP-1 receptor agonist, transforms obesity and diabetes management but requires robust insurance coverage to deliver full benefits. Gasoyan and Rothberg emphasize access hurdles like prior authorizations that delay treatment. Addressing these ensures equitable health improvements amid rising metabolic disorders.
2 min read
Novo Nordisk Introduces $199 Introductory Deal for Wegovy and Ozempic Before Anticipated Price Reductions
Novo Nordisk is launching a special promotion, offering Wegovy and Ozempic at $199 per month for new self-pay patients. This introductory offer is available until March 31, 2026, and is valid for the initial two months of therapy at the lowest dosages.
3 min read